Amgen presents TOWER study data at ASH Annual Meeting

Amgen presented data from its Phase 3 TOWER study at the 58th Annual Meeting and Exposition of the American Society of Hematology this week in San Diego.
"The totality of data for our medicines to be presented at ASH underscores our commitment to helping patients with the toughest conditions through their journey," Amgen Executive Vice President of Research and Development Dr. Sean Harper said. "We look forward to sharing these studies and adding to the body of knowledge in acute lymphoblastic leukemia, multiple myeloma and other hematologic malignancies."
The Phase 3 TOWER study was developed to assess BLINCYTO’s effect on patients who have relapsed or refractory Philadelphia chromosome-negative (PH-) B-cell precursor acute lymphoblastic leukemia. BLINCYTO was compared to standard of care chemotherapy on the patients’ health-related quality of life.
Amgen also presented abstracts at the meeting, including a new analysis of its Phase 3 ENDEAVOR study involving KYPROLIS, which was compared to bortezomib combined with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.
The American Society of Hematology has made all of the abstracts available to view on its website.